OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans

[1]  J. Derrick,et al.  Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial. , 2022, Vaccine.

[2]  M. Pizza,et al.  Synergistic activity of antibodies in the multicomponent 4CMenB vaccine , 2022, Expert review of vaccines.

[3]  R. Rappuoli,et al.  Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect , 2021, NPJ vaccines.

[4]  Brunella Brunelli,et al.  GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines , 2020, Vaccines.

[5]  W. Shafer,et al.  The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae , 2020, bioRxiv.

[6]  S. Ram,et al.  Complement interactions with the pathogenic Neisseriae: clinical features, deficiency states and evasion mechanisms. , 2020, FEBS letters.

[7]  R. Owens,et al.  Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis , 2019, Scientific Reports.

[8]  V. Masignani,et al.  The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology , 2019, Front. Immunol..

[9]  P. De Wals,et al.  The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations , 2019, Expert review of vaccines.

[10]  K. Jolley,et al.  Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens. , 2018, Wellcome open research.

[11]  R. Rappuoli,et al.  Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes , 2018, Scientific Reports.

[12]  D. Granoff,et al.  The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. , 2017, Vaccine.

[13]  P. Balmer,et al.  Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®) , 2016, Postgraduate medicine.

[14]  X. Nassif,et al.  Characterization of the Maf family of polymorphic toxins in pathogenic Neisseria species , 2015, Microbial cell.

[15]  M. Christodoulides.  Neisseria proteomics for antigen discovery and vaccine development , 2014, Expert review of proteomics.

[16]  Min-jun Yu,et al.  Recombinant Neisseria surface protein A is a potential vaccine candidate against Neisseria meningitides serogroup B. , 2014, Molecular medicine reports.

[17]  G. Zuccotti,et al.  A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II) , 2014, Human vaccines & immunotherapeutics.

[18]  M. Stella,et al.  Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine. , 2014, Vaccine.

[19]  J. Poolman,et al.  Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens. , 2014, Vaccine.

[20]  O. Jousson,et al.  Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen , 2014, Journal of extracellular vesicles.

[21]  M. Christodoulides,et al.  Potential of the adhesin complex protein of Neisseria meningitidis for next-generation meningococcal vaccines , 2013, Expert review of vaccines.

[22]  A. Halstensen,et al.  Meningococcal Omp85 in Detergent‐Extracted Outer Membrane Vesicle Vaccines Induces High Levels of Non‐Functional Antibodies in Mice , 2013, Scandinavian journal of immunology.

[23]  S. Black,et al.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV) , 2013, Human vaccines & immunotherapeutics.

[24]  A. Pierleoni,et al.  Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro , 2013, Journal of extracellular vesicles.

[25]  J. Johnston.  An improved counterselection cassette for use in Haemophilus influenzae. , 2012, Gene.

[26]  J. Findlow,et al.  Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles , 2011, Expert opinion on biological therapy.

[27]  P. François,et al.  Transcriptome Analysis of Neisseria meningitidis in Human Whole Blood and Mutagenesis Studies Identify Virulence Factors Involved in Blood Survival , 2011, PLoS pathogens.

[28]  S. Ram,et al.  A Meningococcal Factor H Binding Protein Mutant That Eliminates Factor H Binding Enhances Protective Antibody Responses to Vaccination , 2011, The Journal of Immunology.

[29]  I. Feavers,et al.  Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines , 2011, Expert review of vaccines.

[30]  D. Granoff,et al.  Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. , 2011, Vaccine.

[31]  J. Moon,et al.  A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. , 2011, Vaccine.

[32]  A. Pollard,et al.  Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Ping Chen,et al.  A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. , 2010, Vaccine.

[34]  R. Rappuoli,et al.  Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. , 2010, Vaccine.

[35]  R. Rappuoli,et al.  Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans , 2010, Proceedings of the National Academy of Sciences.

[36]  J. McFadden,et al.  Towards the Immunoproteome of Neisseria meningitidis , 2009, PloS one.

[37]  V. Quesniaux,et al.  Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles. , 2009, Vaccine.

[38]  I. Feavers,et al.  Exploring the proteome of meningococcal outer membrane vesicle vaccines , 2007, Proteomics. Clinical applications.

[39]  J. Langley,et al.  Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. , 2007, Vaccine.

[40]  R. Rappuoli,et al.  A universal vaccine for serogroup B meningococcus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  David H Perlman,et al.  The Meningococcal Vaccine Candidate GNA1870 Binds the Complement Regulatory Protein Factor H and Enhances Serum Resistance , 2006, The Journal of Immunology.

[42]  I. Feavers,et al.  Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254 , 2006, Proteomics.

[43]  A. Gorringe.  Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease? , 2005, Expert review of vaccines.

[44]  K. Mulholland,et al.  MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. , 2005, Vaccine.

[45]  E. Miller,et al.  Meningococcal surrogates of protection--serum bactericidal antibody activity. , 2005, Vaccine.

[46]  I. Feavers,et al.  Characterisation of the Protein Content of a Meningococcal Outer Membrane Vesicle Vaccine by Polyacrylamide Gel Electrophoresis and Mass Spectrometry , 2005 .

[47]  Jeannette Adu-Bobie,et al.  Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870 , 2003, The Journal of experimental medicine.

[48]  J. Tappero,et al.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. , 1999, JAMA.

[49]  D. P. Remeta,et al.  Characterization of the Structure, Function, and Conformational Stability of PorB Class 3 Protein from Neisseria meningitidis , 1998, The Journal of Biological Chemistry.

[50]  N. Cadieux,et al.  Highly Conserved Neisseria meningitidis Surface Protein Confers Protection against Experimental Infection , 1997, The Journal of experimental medicine.

[51]  E. Rosenqvist,et al.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine , 1995, Infection and immunity.

[52]  C. Sacchi,et al.  Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy , 1994, Infection and immunity.

[53]  M. Achtman,et al.  Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly‐cytidine , 1994, Molecular microbiology.

[54]  L. Wetzler,et al.  Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease , 1994, Infection and immunity.

[55]  L. Wetzler,et al.  Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease , 1993, Infection and immunity.

[56]  M. Achtman,et al.  The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. , 1993, The Journal of infectious diseases.

[57]  H. Zanen,et al.  Immunogenicity of meningococcal antigens as detected in patient sera , 1983, Infection and immunity.